{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-299177","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2026-07-09T12:05:21+00:00","discovered_at":"2026-07-09T12:10:00.536294+00:00","generated_at":"2026-07-09T12:10:06.895846+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Forte Biosciences reports positive Phase 1b vitiligo results for FB102; statistically significant FVASI improvement","bullets":["FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p=0.020) vs placebo 7.9% improvement.","Statistically significant improvement observed by day 64 (p=0.023) and continued through week 24 after 12-week treatment.","In subjects with baseline FVASI ≥0.75, FB102 showed 43.2% mean improvement (p=0.006); 58.8% achieved FVASI50, 23.5% FVASI75.","84% (27/32) of FB102-treated subjects improved from baseline to week 24; 0% worsened vs 27% of placebo worsened.","FB102 demonstrated strong safety profile with only mild to moderate AEs, comparing favorably to placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-299177","json":"https://secwatch.observer/filing/0001193125-26-299177.json","markdown":"https://secwatch.observer/filing/0001193125-26-299177.md","text":"https://secwatch.observer/filing/0001193125-26-299177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526299177/0001193125-26-299177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526299177/d170175d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T12:10:06.895846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}